Suppliers and packagers for ENTRESTO

ENTRESTO

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Novartis Pharms Corp	ENTRESTO	sacubitril; valsartan	TABLET;ORAL	207620	NDA	Novartis Pharmaceuticals Corporation	0078-0659-20	60 TABLET, FILM COATED in 1 BOTTLE (0078-0659-20)	2015-07-07
Novartis Pharms Corp	ENTRESTO	sacubitril; valsartan	TABLET;ORAL	207620	NDA	Novartis Pharmaceuticals Corporation	0078-0659-67	180 TABLET, FILM COATED in 1 BOTTLE (0078-0659-67)	2015-07-07
Novartis Pharms Corp	ENTRESTO	sacubitril; valsartan	TABLET;ORAL	207620	NDA	Novartis Pharmaceuticals Corporation	0078-0696-20	60 TABLET, FILM COATED in 1 BOTTLE (0078-0696-20)	2015-07-07
Novartis Pharms Corp	ENTRESTO	sacubitril; valsartan	TABLET;ORAL	207620	NDA	Novartis Pharmaceuticals Corporation	0078-0696-67	180 TABLET, FILM COATED in 1 BOTTLE (0078-0696-67)	2015-07-07
Novartis Pharms Corp	ENTRESTO	sacubitril; valsartan	TABLET;ORAL	207620	NDA	Novartis Pharmaceuticals Corporation	0078-0777-20	60 TABLET, FILM COATED in 1 BOTTLE (0078-0777-20)	2015-07-07
Novartis Pharms Corp	ENTRESTO	sacubitril; valsartan	TABLET;ORAL	207620	NDA	Novartis Pharmaceuticals Corporation	0078-0777-67	180 TABLET, FILM COATED in 1 BOTTLE (0078-0777-67)	2015-07-07

Entresto API Manufacturing: Key Suppliers and Patent Landscape

Last updated: February 19, 2026

This report identifies the primary suppliers for the active pharmaceutical ingredients (APIs) used in Entresto (sacubitril/valsartan) and analyzes the patent landscape impacting their production and market access. Entresto is a vital medication for heart failure, driving significant demand for its constituent APIs. Understanding supplier capabilities and patent protection is critical for assessing supply chain resilience and future market opportunities.

What is Entresto and its Active Pharmaceutical Ingredients?

Entresto is a fixed-dose combination medication developed by Novartis. It contains two active agents: sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker (ARB). These work synergistically to reduce the risk of cardiovascular death and hospitalization in patients with heart failure with reduced ejection fraction.

• Sacubitril: A prodrug that is metabolized to its active form, LBQ657, which inhibits neprilysin. Neprilysin is an enzyme that degrades natriuretic peptides. By inhibiting neprilysin, sacubitril increases the levels of these natriuretic peptides, which have beneficial effects on the cardiovascular system.
• Valsartan: An ARB that blocks the action of angiotensin II, a hormone that causes vasoconstriction and sodium retention. By blocking angiotensin II, valsartan leads to vasodilation and reduced sodium and water retention, lowering blood pressure.

Who Manufactures the APIs for Entresto?

The manufacturing of APIs for a complex drug like Entresto involves specialized chemical synthesis and stringent quality control. While Novartis holds the primary marketing authorization, the production of sacubitril and valsartan APIs is often outsourced to contract manufacturing organizations (CMOs) and specialized API manufacturers. Identifying these suppliers is crucial for market intelligence.

Primary API Suppliers Identified:

Based on available regulatory filings, patent litigation, and industry reports, the following entities are known or highly likely to be involved in the supply chain for sacubitril and/or valsartan APIs:

• Granules India Limited: A major Indian pharmaceutical company specializing in APIs. Granules has been publicly identified as a supplier of valsartan and potentially sacubitril. Their facilities are approved by major regulatory bodies, including the US FDA and EMA. Granules' business model focuses on backward integration and cost-effective manufacturing, making them a significant player in the generic API market. [1]
• Divi's Laboratories Limited: Another prominent Indian API manufacturer with a strong reputation for complex chemistry and large-scale production. Divi's is a known supplier for various high-volume APIs, and its involvement in the Entresto supply chain for either sacubitril or valsartan is highly probable given its capabilities and market position. [2]
• Jubilant Pharmova Limited (formerly Jubilant Life Sciences): This company has a significant API manufacturing segment. Jubilant has a broad portfolio of APIs and is recognized for its expertise in heterocyclic chemistry, which is relevant for sacubitril synthesis.
• Hetero Drugs Limited: A large Indian pharmaceutical company with extensive API manufacturing capabilities. Hetero is a significant player in the global API market and is likely to be involved in supplying either valsartan or sacubitril, or both, particularly for the generic market.
• Dr. Reddy's Laboratories: While primarily known for finished dosage forms, Dr. Reddy's also has a substantial API manufacturing arm. They are a significant supplier of various APIs, and their capabilities align with the production requirements for Entresto's components.
• Various Chinese API Manufacturers: China is a dominant force in global API production. Numerous Chinese companies, operating under different trade names and often serving as intermediaries or direct suppliers, are involved in the manufacturing of both valsartan and sacubitril. These include companies like Zhejiang Huahai Pharmaceutical Co., Ltd., which has faced regulatory scrutiny in the past regarding valsartan impurities, highlighting the importance of rigorous quality control across all suppliers. [3]

Note: The specific contracts and relationships between Novartis and its API suppliers are proprietary. However, regulatory filings (e.g., Drug Master Files - DMFs) submitted to agencies like the US Food and Drug Administration (FDA) often list manufacturers, providing indirect insights into the supply chain. Furthermore, patent litigation involving generic manufacturers seeking to market their versions of Entresto frequently names API suppliers involved in the development and production of those generic APIs.

What is the Patent Landscape for Entresto APIs?

The patent landscape for Entresto is multifaceted, covering not only the compound patents for sacubitril and valsartan but also patents related to manufacturing processes, polymorphic forms, and formulations. This complex web of intellectual property rights significantly influences market entry for generic competitors and the operations of API suppliers.

Key Patents and Expiries:

• Sacubitril (LCZ696):

  • Compound Patent: The primary compound patent for sacubitril is crucial. While specific patent numbers and jurisdictions vary, the original patent protection for the sacubitril molecule itself has been a significant barrier to generic entry. Novartis has actively defended this intellectual property.
  • Process Patents: Patents covering specific synthetic routes and intermediate steps in the production of sacubitril are also critical. Innovator companies often patent novel or improved manufacturing processes to extend their exclusivity and make it harder for generics to replicate the API cost-effectively and efficiently.
  • Formulation and Polymorph Patents: Patents related to specific crystalline forms (polymorphs) of sacubitril and its formulations can also provide additional layers of protection.

• Valsartan:

  • Compound Patent: Valsartan is an older drug, and its primary compound patents have expired in many major markets. This has allowed for the development and marketing of generic valsartan.
  • Process Patents: However, Novartis may hold patents on specific, improved, or cost-effective manufacturing processes for valsartan that are incorporated into the Entresto product. Generic manufacturers must navigate these process patents to avoid infringement.
  • Combination Patents: The unique combination of sacubitril and valsartan in Entresto is also protected by patents, in addition to the individual compound patents.

• Entresto (Sacubitril/Valsartan Fixed-Dose Combination):

  • Composition of Matter Patent: Patents covering the specific combination and ratio of sacubitril and valsartan are central to Entresto's market exclusivity.
  • Manufacturing Process Patents: Novel manufacturing processes for producing the combined API or the finished dosage form are also protected.
  • Dosage and Administration Patents: Patents related to specific dosing regimens or methods of administration can offer further protection.
  • Polymorph and Salt Patents: Patents on specific crystalline forms or salts of the combined drug product or its components can also exist.

Patent Expiration and Generic Entry:

The expiry of key patents, particularly the compound patent for sacubitril and patents related to the combination, marks the critical window for generic manufacturers and their API suppliers.

• US Market: The principal patent protecting Entresto in the US was set to expire in November 2027. However, legal challenges and patent disputes can alter these timelines. In late 2023, a US court invalidated key patents covering Entresto, paving the way for potential earlier generic entry. [4] This ruling, if upheld on appeal, would significantly accelerate the availability of generic sacubitril/valsartan.
• European Market: Patent expiry dates in Europe vary by country due to different patent lifespans and validation processes. Novartis has sought Supplementary Protection Certificates (SPCs) to extend patent protection in various European jurisdictions.
• Other Markets: Patent landscapes in Canada, Australia, Japan, and other key markets will have their own specific expiry dates and legal challenges.

Impact of Patent Expiries on API Suppliers:

• Increased Demand for Generic APIs: As primary patents expire and generic versions of Entresto enter the market, demand for generic-grade sacubitril and valsartan APIs will surge. This presents a significant opportunity for established API manufacturers like Granules India, Divi's Laboratories, Hetero Drugs, and others.
• Navigating Process Patents: Generic API suppliers must carefully analyze the patent landscape to ensure their manufacturing processes do not infringe on existing process patents held by Novartis or other entities. This may involve developing novel, non-infringing synthetic routes.
• Quality and Regulatory Compliance: Generic API suppliers must meet the same rigorous quality standards (cGMP) and regulatory requirements (FDA, EMA) as the innovator's suppliers. This includes demonstrating bioequivalence of their API and ensuring the absence of impurities, such as those seen with valsartan from certain manufacturers in the past. [3]
• Competition and Pricing Pressure: The entry of multiple generic API suppliers will likely lead to increased competition and downward pricing pressure for sacubitril and valsartan APIs.

Regulatory Considerations for Entresto API Manufacturing

Manufacturing APIs for a drug like Entresto is subject to strict regulatory oversight by health authorities worldwide. Compliance is paramount for any API supplier aiming to enter or remain in this market.

Key Regulatory Requirements:

• Current Good Manufacturing Practices (cGMP): All API manufacturing facilities must adhere to cGMP guidelines established by regulatory bodies such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. This covers all aspects of production, including facility design, equipment, personnel training, raw material control, process validation, quality control testing, and record-keeping.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. A DMF contains confidential, detailed information about the manufacturing process, facilities, quality controls, and stability of the API. This allows regulatory agencies to review the API information when evaluating a finished drug product application without disclosing proprietary details to the drug product manufacturer.
• Impurity Profiling and Control: Regulatory agencies place a high emphasis on identifying, quantifying, and controlling impurities in APIs. The valsartan impurity issue (N-nitrosodimethylamine - NDMA) that affected some valsartan products highlighted the critical need for robust impurity control strategies. [3] API suppliers for Entresto must demonstrate comprehensive control over potential impurities in both sacubitril and valsartan.
• Stability Testing: Comprehensive stability studies are required to establish the shelf-life of the API under various storage conditions. This data is crucial for ensuring the quality and efficacy of the finished drug product.
• Site Inspections: Regulatory agencies conduct routine inspections of API manufacturing facilities to ensure ongoing compliance with cGMP and other regulations.

Specific Considerations for Sacubitril and Valsartan:

• Chiral Synthesis: Sacubitril involves chiral centers, requiring enantioselective synthesis or resolution steps to produce the desired stereoisomer. Control over stereochemistry is critical for efficacy and safety.
• Complex Synthesis Routes: Both sacubitril and valsartan involve multi-step chemical synthesis. Optimizing these routes for yield, purity, and cost-effectiveness while ensuring regulatory compliance is a significant challenge.
• Supply Chain Transparency: Increasing regulatory focus on supply chain integrity requires robust traceability and transparency from raw material sourcing through to the final API.

Market Outlook and Strategic Implications for API Suppliers

The market for Entresto APIs is poised for significant growth, driven by the drug's established efficacy and the impending expiry of key patents, which will open doors for generic competition.

Growth Drivers:

• Expanding Heart Failure Treatment: Heart failure is a growing global health burden, and Entresto has become a cornerstone therapy for a significant patient population.
• Genericization: The anticipated entry of generic Entresto will broaden access and increase overall volume demand for sacubitril and valsartan APIs.
• Emerging Markets: Increased healthcare access and prescription of Entresto in emerging economies will contribute to sustained demand.

Strategic Implications for API Suppliers:

• Investment in Capacity: API manufacturers looking to capitalize on generic Entresto opportunities will need to invest in scaled-up manufacturing capacity for sacubitril and valsartan.
• Process Innovation: Developing non-infringing and cost-efficient synthetic routes will be a key differentiator.
• Regulatory Readiness: Maintaining impeccable regulatory compliance and robust quality systems is essential for securing supply contracts with generic finished-dose manufacturers.
• Supply Chain Security: Establishing secure and reliable sourcing of raw materials and intermediates is critical to mitigate supply chain disruptions.
• Partnerships: Forming strategic partnerships with generic finished-dose manufacturers can provide early market access and predictable demand.

The dynamic patent landscape, particularly the recent US court ruling invalidating key Entresto patents, suggests that the timeline for generic entry may be significantly shorter than previously anticipated. API suppliers must remain agile and monitor legal developments closely to adjust their strategies accordingly.

Key Takeaways

• Entresto's APIs, sacubitril and valsartan, are manufactured by specialized API producers, including Granules India, Divi's Laboratories, Jubilant Pharmova, Hetero Drugs, and Dr. Reddy's Laboratories, alongside numerous Chinese manufacturers.
• The patent landscape for Entresto is complex, with patents covering compounds, manufacturing processes, and the combination itself.
• Key US patents protecting Entresto were recently invalidated by a US court, potentially accelerating generic entry.
• Generic competition will drive increased demand for sacubitril and valsartan APIs, creating opportunities for established and new suppliers.
• API suppliers must prioritize cGMP compliance, robust impurity control, and navigating process patents to succeed in the Entresto API market.

Frequently Asked Questions

1. Which specific impurities have been a concern in valsartan API manufacturing, and how are these being addressed for Entresto? The primary concern with valsartan API has been the presence of nitrosamine impurities, particularly N-nitrosodimethylamine (NDMA). Manufacturers are addressing this by optimizing synthetic routes to avoid the formation of these impurities, implementing rigorous analytical testing methods for detection, and ensuring stringent quality control at every stage of the manufacturing process. Regulatory agencies require comprehensive impurity profiling and control strategies.

2. What is the typical lead time for a new API supplier to be approved for Entresto production? The lead time for a new API supplier to be approved for Entresto production can vary significantly but generally ranges from 12 to 24 months. This period includes process validation, scale-up, stability studies, filing Drug Master Files (DMFs), and undergoing regulatory inspections by agencies like the FDA and EMA. If the supplier is intended for the innovator product, the timeline may be longer due to proprietary development and qualification processes. For generic products, the timeline depends on the generic manufacturer's filing schedule and the regulatory review process.

3. How does the invalidation of Entresto patents in the US impact the supply of APIs for innovator versus generic versions? The invalidation of key patents in the US significantly impacts the market for generic Entresto. It signals that generic manufacturers can likely introduce their products sooner, thus increasing the immediate demand for generic-grade sacubitril and valsartan APIs from suppliers who have developed non-infringing processes. For the innovator (Novartis), while the patent protection is weakened in the US, they will likely continue to rely on their established suppliers. However, the impending generic competition will pressure pricing for the innovator product as well.

4. Are there any specific challenges in the synthesis of sacubitril compared to valsartan that affect API supplier selection? Yes, sacubitril synthesis presents unique challenges. It is a prodrug that requires chiral synthesis to produce the correct stereoisomer, demanding specialized enantioselective catalysis or resolution techniques. Additionally, sacubitril's complex organic structure involves multiple synthetic steps, requiring sophisticated chemistry expertise and control over reaction conditions to ensure high purity and yield. Valsartan, while also a complex molecule, has been produced for a longer period, and its synthesis routes are more established, though process optimization remains a competitive factor.

5. What role do regional regulatory differences play for API suppliers targeting different markets for Entresto? Regional regulatory differences are critical. API suppliers must comply with the specific requirements of each target market's regulatory authority, such as the FDA in the US, EMA in Europe, PMDA in Japan, and others. This includes variations in DMF content requirements, inspection protocols, and impurity limits. For example, nitrosamine impurity guidelines have seen evolving specifics in different regions. Suppliers must ensure their API and supporting documentation meet the most stringent standards applicable to their intended markets, often requiring separate regulatory filings and inspections for each region.

Citations

[1] Granules India Limited. (n.d.). About Us. Retrieved from https://www.granulesindia.com/about-us/

[2] Divi's Laboratories Limited. (n.d.). Products. Retrieved from https://www.divislabs.com/products/

[3] U.S. Food & Drug Administration. (2018, December 13). Information about valsartan. FDA.gov. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/information-about-valsartan

[4] Bloomberg Law. (2023, November 17). Novartis Loses Key Patents for Heart Drug Entresto in U.S. Bloomberg Law. Retrieved from https://news.bloomberglaw.com/ip-law/novartis-loses-key-patents-for-heart-drug-entresto-in-u-s